Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates

Carbone, M.; Pennisi, Maria Grazia; Masucci, Marisa; Sarro, Angela De; Giannone, M.; Fera, M. T.

doi:10.1016/s0378-1135(01)00349-2

Cited by 24 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No difference in marbofloxacin susceptibility between 1989 and 2000 could be observed in classical urinary pathogenic strains (mainly E. coli), respiratory pathogenic strains (mainly Pasteurellaceae), dermatological pathogenic strains (mainly S. intermedius, S. aureus) or other pets' bacteria (P. aeruginosa). Moreover, in the more recent publications [1,8,10] and others [11] the marbofloxacin activity was comparable with those obtained and was effective against others pets' pathogenic strains not studied by us, such as the Enterobacteriaceae, S. aureus, Salmonella spp. and Bordetella bronchiseptica.…”

Section: Discussionsupporting

confidence: 80%

A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets

Meunier

Acar

Martel

et al. 2004

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 80%

A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets

Meunier

Acar

Martel

et al. 2004

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…It was well known that enrofloxacin prevented the synthesis of bacterial DNA by gyrase, the PAE might represent the time for it to dissociate from the receptor binding sites and to diffuse out of the bacterium. It was generally believed that PAE was concentration dependent and directly related to the exposure time [17]. In this study, PAE of enrofloxacin was evaluated by exposure of isolate AH10 to it at 2, 4, and 8 times MIC for 1 h (Figure.…”

Section: Resultsmentioning

confidence: 99%

Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance

Wang

Yang

et al. 2013

BMC Vet Res

View full text Add to dashboard Cite

BackgroundAntibiotic resistance has become a serious global problem and is steadily increasing worldwide in almost every bacterial species treated with antibiotics. In aquaculture, the therapeutic options for the treatment of A. hydrophila infection were only limited to several antibiotics, which contributed for the fast-speed emergence of drug tolerance. Accordingly, the aim of this study was to establish a medication regimen to prevent drug resistant bacteria. To determine a rational therapeutic guideline, integrated pharmacodynamics and pharmacokinetics parameters were based to predict dose and dosage interval of enrofloxacin in grass carp Ctenopharyngodon idella infected by a field-isolated A. hydrophila strain.ResultsThe pathogenic A. hydrophila strain (AH10) in grass carp was identified and found to be sensitive to enrofloxacin. The mutant selection window (MSW) of enrofloxacin on isolate AH10 was determined to be 0.5 - 3 μg/mL based on the mutant prevention concentration (MPC) and minimum inhibitory concentration (MIC) value. By using high-performance liquid chromatography (HPLC) system, the Pharmacokinetic (PK) parameters of enrofloxacin and its metabolite ciprofloxacin in grass carp were monitored after a single oral gavage of 10, 20, 30 μg enrofloxacin per g body weight. Dosing of 30 μg/g resulted in serum maximum concentration (Cmax) of 7.151 μg/mL, and concentration in serum was above MPC till 24 h post the single dose. Once-daily dosing of 30 μg/g was determined to be the rational choice for controlling AH10 infection and preventing mutant selection in grass carp. Data of mean residue time (MRT) and body clearance (CLz) indicated that both enrofloxacin and its metabolite ciprofloxacin present similar eliminating rate and pattern in serum, muscle and liver. A withdraw time of more than 32 d was suggested based on the drug eliminating rate and pharmacokinetic model described by a polyexponential equation.ConclusionsBased on integrated PK/PD parameters (AUC/MIC, Cmax/MIC, and T>MPC), the results of this study established a principle, for the first time, on drawing accurate dosing guideline for pharmacotherapy against A. hydrophila strain (AH10) for prevention of drug-resistant mutants. Our approach in combining PK data with PD parameters (including MPC and MSW) was the new effort in aquaculture to face the challenge of drug resistance by drawing a specific dosage guideline of antibiotics.

show abstract

“…Despite the availability of four veterinary fluoroquinolones, few studies have compared the susceptibility of a representative selection of canine and feline bacterial isolates to these agents in vitro 1,4–7 . Although widespread use of fluoroquinolones in humans has selected for bacterial resistance to fluoroquinolones, 8 there is limited data on this phenomenon in a veterinary context.…”

mentioning

confidence: 99%

Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones

et al. 2008

View full text Add to dashboard Cite

This is the first report comparing the MICs for all veterinary fluoroquinolones currently available in Australia for a representative sample of canine and feline E coli and canine S intermedius isolates. Importantly, this study identified 12 of 59 canine E coli isolates resistant to fluoroquinolones and identified the development of low level resistance in canine E coli to ciprofloxacin and enrofloxacin and canine S intermedius to amoxycillin-clavulanate.

show abstract

Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates

Cited by 24 publications

References 12 publications

A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets

A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets

Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance

Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones

Contact Info

Product

Resources

About